Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › retifanlimab

retifanlimab

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of retifanlimab

8 trials tracked of retifanlimab: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 98 citations.

8Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 2 Phase 2 5 Phase 1 1
  1. Phase 3 Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Completed · 98 cited
  2. Phase 3 Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). Completed · 26 cited
  3. Phase 2 A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) Completed
  4. Phase 2 A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201) Completed
  5. Phase 2 Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas Completed
  6. Phase 2 Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS) Completed
Show 2 more trials
  1. Phase 2 A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) Completed
  2. Phase 1 Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Zynyz (retifanlimab-dlwr) for Metastatic Anal Canal Cancer and Merkel Cell Carcinoma
Oncology FDA Approval
FDA Approves Zynyz (retifanlimab-dlwr) for Metastatic Anal Canal Cancer and Merkel Cell Carcinoma FDA approves new drug Zynyz for two rare and aggressive types of cancer
The FDA has approved Zynyz, a PD-1 blocking antibody, for two indications: first-line treatment of inoperable locally recurrent or metastati…
FDA approves new drug Zynyz to treat two rare and aggressive cancers: advanced anal cancer and Merkel cell carcinoma.
FDA Apr 2, 2026